Allarity Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALLR research report →
Companywww.allarity.com
Allarity Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.
- CEO
- Thomas H. Jensen
- IPO
- 2021
- Employees
- 6
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $23.71M
- P/E
- -2.12
- P/S
- 68.72
- P/B
- 3.44
- EV/EBITDA
- -2.29
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 107.54%
- Op Margin
- -3552.75%
- Net Margin
- -3260.58%
- ROE
- -109.94%
- ROIC
- -43.13%
Growth & Income
- Revenue
- $320.00K · 0.00%
- Net Income
- $-11,231,000 · 54.19%
- EPS
- $-0.78 · 95.06%
- Op Income
- $-12,605,000
- FCF YoY
- 15.99%
Performance & Tape
- 52W High
- $2.35
- 52W Low
- $0.77
- 50D MA
- $1.28
- 200D MA
- $1.25
- Beta
- 0.38
- Avg Volume
- 175.56K
Get TickerSpark's AI analysis on ALLR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 28, 26 | Jensen Thomas | other | 200,000 |
| Jan 7, 26 | Hoeiland Jesper | other | 25,000 |
| Jun 10, 25 | Hoeiland Jesper | other | 0 |
| Jan 28, 26 | McLaughlin Gerald W. | other | 45,000 |
| Jan 28, 26 | Graff Jeremy R. | other | 133,333 |
| Jan 28, 26 | Ervin Jeffrey S | other | 150,000 |
| Jan 7, 26 | Graff Jeremy R. | other | 133,333 |
| Sep 30, 25 | Graff Jeremy R. | other | 39,494 |
| Sep 30, 25 | Graff Jeremy R. | other | 39,494 |
| Sep 30, 25 | Graff Jeremy R. | other | 14,613 |
Our ALLR Coverage
We haven't published any research on ALLR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALLR Report →